Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of RV521 Formulations in Healthy Adults
NCT04065698Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sisunatovir in respiratory syncytial virus infection (RSV), sponsored by Pfizer. Primary endpoints: Time to maximum plasma concentration, Terminal half-life and 3 more. Started Aug 2019; status: completed.
02
Drugs
sisunatovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04065698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04065698.